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Abstract: Quaternary derivatives of 1,4-diazabicyclo[2.2.2]octane (DABCO) and of quinuclidine 
surfactants were used to develop oil-in-water nanoemulsions with the purpose of selecting the best 
long-term stable nanoemulsion for the ocular administration of triamcinolone acetonide (TA). The 
combination of the best physicochemical properties (i.e., mean droplet size, polydispersity index, 
zeta potential, osmolality, viscoelastic properties, surface tension) was considered, together with 
the cell viability assays in ARPE-19 and HMC3 cell lines. Surfactants with cationic properties have 
been used to tailor the nanoemulsions’ surface for site-specific delivery of drugs to the ocular 
structure for the delivery of TA. They are tailored for the eye because they have cationic properties 
that interact with the anionic surface of the eye. 
Keywords: cationic nanoemulsions; DABCO surfactants; quinuclidine surfactants; ocular 
administration; triamcinolone acetonide; age-related macular degeneration; HMC3 cell line; ARPE-
19 cell line 
 
1. Introduction 
Nanoemulsions are a subcategory of emulsion characterized by a mean droplet size 
between 20 and 500 nm. Nanoemulsions are composed of two immiscible liquids in which 
the droplets of one liquid (dispersed phase or inner phase) are dispersed in another liquid 
(continuous phase or external phase) and can be classified into two types, namely, oil-in-
water (o/w) and water-in-oil (w/o) [1]. In the production of emulsions and nanoemulsions, 
surfactants are usually required to stabilize the formulations and prolong their shelf life 
[2]. Surfactants are molecules that rest at the interface between oil and water to stabilize 
emulsions through different mechanisms, either by steric stabilization and/or by 
electrostatic repulsion [3]. Surfactants used to stabilize the nanoemulsions can be ionic or 
nonionic. The most commonly used ionic surfactants are sodium dodecyl sulfate (as 
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anionic) and the cetyltrimethylammonium bromide (as cationic) and other typical 
nonionic surfactants, such as polysorbates and sorbitan esters. Other less common types 
of surfactants include natural biopolymers, such as whey protein and gum arabic [4,5]. 
Nanoemulsions can be obtained by high-energy methods or by low-energy methods. The 
high-energy methods require the use of high-pressure homogenization (HPH) and/or 
ultrasonication (US). In the HPH process, the size of the obtained droplets is governed by 
the pressure, design and size gab of the homogenization valve [6]. In the US process, the 
electrical input induces pressure fluctuations that produce cavitation bubbles. The break 
of the cavitation bubbles generates shear forces that promote the break of bigger drops 
into smaller drops [7]. In opposition to high-energy methods, low-energy methods only 
need the mixture of the components of the formulation using a stirrer [8,9]. 
Due to their properties, nanoemulsions are attractive delivery systems for poorly 
water-soluble drugs to improve their solubility and increase bioavailability [10,11]. In the 
nanoemulsions created to deliver hydrophobic or lipophilic drugs, the drug is dissolved 
in the oil phase to produce o/w nanoemulsions. Triamcinolone acetonide (TA) is a potent 
synthetic steroid with known anti-inflammatory and anti-angiogenic activities [12]. TA is 
approved by the FDA as a glucocorticosteroid, and has been widely used by intravitreal 
administration in the treatment of diabetic macular edema, vitreoretinopathy, uveitis, 
sympathetic ophthalmia, proliferative diabetic retinopathy and age-related macular 
degeneration (AMD) [13–15]. The intravitreal injection of TA is widely reported to reduce 
leakage from choroid neovascularization. Nevertheless, the hydrophobicity and lack of 
solubility of TA are a challenge for the development of ocular drug delivery systems. The 
increase in drug solubility will result in increased bioavailability, attributed to the 
enhanced permeation through ocular tissues and intracellular transport. Besides, the use 
of controlled/prolonged delivery systems may also contribute to reduce the systemic 
toxicity of the drug [16]. 
Age-related macular degeneration (AMD) is one of the main causes of severe and 
irreversible loss of vision in the elderly population [17]. In the last few years, efforts have 
been made to understand the pathophysiology of neovascularization in AMD. This 
knowledge allows developing new strategies in the progress of medical treatments for 
AMD. There are two types of AMD, namely, the nonexudative (dry) AMD and exudative 
(wet) AMD. Approximately 10–20% of patients with dry AMD progress to the wet form 
of AMD, in which pathologic choroidal neovascular membranes grow under the retina 
[18]. In wet AMD, there is a growth of abnormal new blood vessels from the choroidal 
vasculature. This specific process involves the presence of an angiogenic and 
inflammation stimulant inducing the wound-healing cascade [19]. Steroids inhibit the 
migration and the activity of the cells that stimulate the inflammatory response and 
wound repair. Another property of corticosteroids is the suppression of inflammation and 
the immune response, and they are able to reduce the permeability of the blood–retinal 
barrier (BRB). Additionally, some corticosteroids have an anti-angiogenic effect [20]. TA 
has been considered a safe and effective drug for ophthalmic administration, as TA is well 
tolerated by the ocular tissues and retains its activity for months after one intravitreal 
injection. Intravitreal injection is, however, linked to severe complications and side effects, 
such as subconjunctival hemorrhage, retinal detachments, vitreous hemorrhages, 
intraocular inflammation [21] and increased intraocular pressure [22], among others 
[23,24]. In this work, we describe the development of nanoemulsions to deliver TA into 
microglia and human retinal pigment epithelial cell line cells, with the aim to increase its 
therapeutic effect. 
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2. Materials and Methods 
2.1. Materials 
Polysorbate 80 (Tween 80®) was purchased from Uniqema (Everberg, Belgium). 
Soybean oil, glycerol and triamcinolone acetonide were purchased from Sigma-Aldrich 
(Steinheim, Germany). P188 (Kolliphor 188 was purchased from BASF Schweiz AG 
(Kaisten, Germany). Cationic surfactants (mono- and dicationic DABCO and 
quinuclidine) were produced at the Arbuzov Institute of Organic and Physical Chemistry 
of the FRC Kazan Scientific Center of Russian Academy of Sciences. Ultra-purified water 
was obtained from the Milli® Q Plus system, home supplied. Human retinal pigment 
epithelial cell line (ARPE-19) and human microglial clone 3 cell line (HMC3) were 
obtained from the American Type Culture Collection (ATCC®) and used at passages 7–20 
and 21–27, respectively. Dulbecco’s modified Eagle medium nutrient mixture F-12 
(DMEM/F-12), fetal bovine serum (FBS), 100 U/mL penicillin, 100 μg/mL streptomycin, 
trypsin–EDTA and Hank’s balanced salt solution (HBSS) were purchased from Gibco 
(Invitrogen Corporation, Waltham, MA, USA). Amicon® Ultra Centrifugal Filters, 0.5 mL 
50K, were purchased from Merck Millipore Ltd. (Darmstadt, Germany). 
2.2. Production of Nanoemulsions 
Nanoemulsions were produced based on the method described by Fernandes et al. 
[25]. Briefly, an oil phase composed of soybean oil, tween 80 and a DABCO surfactant was 
heated in a water bath at 50 °C, followed by its dispersion in an aqueous solution 
composed of glycerol, poloxamer 188 and water, heated in a water bath at the same 
temperature of 50 °C, using a probe sonication Qsonica 4435 Q55 Sonicator Microprobe, 
1/4”, with 0.635 cm of tip diameter (Sonics vibracell, Newtown, Connecticut, CT, USA) for 
5 min (Table 1). The final step was the transfer of the hot nanoemulsion to an ice bath (0 
°C) to allow cooling down. For the production of TA-loaded nanoemulsions, the drug was 
added to the inner oily phase before dispersion into the aqueous phase. 
2.3. Particle Size Parameters and Zeta Potential 
The mean particle size and polydispersity index (PI) were determined in triplicate by 
dynamic light scattering (DLS) using the Zetasizer Nano ZS (Malvern, Worcestershire, 
UK) at 25 °C. The values are given as the mean of triplicate runs per sample. The 
nanoemulsions were diluted in Milli Q water to a suitable concentration (1:1) to prevent 
multiple scattering. 
The zeta potential analysis (ZP) was taken by electrophoretic light scattering using a 
Zetasizer Nano ZS (Malvern, Worcestershire, UK). The samples were taken in a Flow Cell 
at 25 °C, diluted with Milli-Q water (1:1) to prevent multiple scattering. The software 
system incorporated the Helmholtz–Smoluchowski equation, which was used to calculate 
the ZP. The obtained values are presented as the mean of triplicate runs per sample. 
2.4. Osmolality 
The values of osmolality of the nanoemulsions were recorded using the 
EquipWescor Vapor Pressure Osmometer VAPRO equipment, model 5520 (Logan, Utah, 
UT, USA). Ten microliters of the nanoemulsion were positioned into a solute-free paper 
disc in the sample holder of the equipment. The cycle measurement initiated when the 
sample holder was pushed into the equipment, taking 80 s. The results of Vapro are 
displayed in standard international units, mOsm/kg. 
2.5. Minimum Inhibitory Concentration 
The in vitro antifungal activity of nanoemulsions was evaluated against Candida 
albicans, by estimating the minimum inhibitory concentration (MIC), as previously 
described by Pashirova et al. [26]. The antifungal assay was performed in Sabouraud 
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dextrose broth (HiMedia Laboratories Pvt. Ltd. Mumbai, India) (density 2 × 104 cfu/mL), 
composed of peptone (10 g) and glucose (40 g), dissolved in purified water (1 L). Broth 
was previously adjusted to pH 5.6, followed by autoclaving for 15 min at 121 °C. The 
experiments were carried out in triplicate. 
2.6. Rheological Behavior 
The rheology of nanoemulsions was analyzed by applying a frequency sweep test, 
using a Rheo Stress RS 100 (Haake Instruments, Karlsruhe, Germany), a cone-and-plate 
test geometry rheometer with a plate diameter of 20 mm and a cone angle 48°. An oscilla-
tion frequency sweep test was performed over a frequency range from 0 to 10 Hz. The 
storage modulus (G’), loss modulus (G’’) and the complex viscosity (η*) of nanoemulsions 
were established as a function of the frequency with a constant stress amplitude of 5 Pa, 
i.e., in the region of linear viscoelastic. 
2.7. Encapsulation Efficiency and Loading Capacity 
An indirect method was used to assess the encapsulation parameters of TA in the 
nanoemulsions. The latter were firstly submitted to ultracentrifugation, and the superna-
tant was measured in the plate reader to calculate the drug concentration. A calibration 
curve was made by diluting the TA in Milli-Q water with 20% of ethanol to ensure the 
total dilution (0.6−600 μg/mL). The calibration curve was built upon the readings of TA, 
at 240 nm, in a BioTek Synergy HT (BIOTek Instruments, Winooski, VT, USA) plate 
reader. The encapsulation efficiency (EE) and loading capacity (LC) of TA in nanoemul-
sions were calculated as follows: EE% = 𝑊 −𝑊𝑊 × 100 (1) 
LC% = 𝑊 −𝑊𝑊 −𝑊 +𝑊 × 100 (2) 
where WTA is the mass of triamcinolone acetonide (TA) used to produce the loaded 
nanoemulsions, WO is the mass of soybean oil used for the production of nanoemulsions 
and Ws is the mass of TA quantified in the supernatant. Briefly, nanoemulsions were firstly 
passed through centrifugal filter units with a cut-off of 50k, i.e., 50,000 nominal molecular 
weight limit (NMWL), and ultra-centrifuged for 15 min at 13,400× g in a Beckman Op-
tima™ Ultracentrifuge (Optima™ XL, Indianapolis, IN, USA) and with quantification de-
termined in the supernatant in the plate reader at 240 nm. Centrifugal filter units used in 
the ultracentrifugation had a cut-off of 50k, i.e., 50,000 nominal molecular weight limit 
(NMWL). 
2.8. Surface Tension 
For the determination of the surface tension, the optical contact angle was recorded 
using an OCA 15 plus (DataPhysics Instruments GmbH, Filderstadt, Germany). OCA 15 
plus is a video-based optical contact angle measurement device provided with an elec-
tronic syringe and connecter to a video camera. SCA20 software (Data Physics Instru-
ments GmbH, Germany) was used for image analysis and subsequent calculation of 
nanoemulsion surface tension. 
2.9. Cell Culture 
Human retinal pigment epithelial cell line (ARPE-19) and human microglial clone 3 
cell line (HMC3) were used at passages 7−20 and 21−27, respectively. Both cell lines were 
grown in Dulbecco’s modified Eagle medium nutrient mixture F-12 (DMEM/F-12) sup-
plemented with 10% fetal bovine serum (FBS), and 1% antibiotics (100 U/mL penicillin 
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and 100 μg/mL streptomycin). The above-mentioned cell cultures were maintained in a 
humidified incubator at 37 °C with 5% CO2. 
2.9.1. Cytotoxicity Assay (AlamarBlue®) 
ARPE-19 and HMC3 cells were plated at a density of 50,000 cells/well in a 96-well 
plate (Costar, Cambridge, MA, USA) and incubated at 37 °C for 24 h in culture medium. 
After this time, the cells were treated with 200 μL of medium containing different concen-
trations of TA or 200 μL of nanoemulsions at increasing concentrations (5%, 10% and 20%) 
for 24 h. Cells treated with fresh medium served as a negative control, and treatment with 
1 mM H2O2, for 24 h, served as a positive control. Cell viability was assessed using Ala-
marBlue® assay. Briefly, AlamarBlue® is a cell viability assay with a blue reagent dye 
called resazurin. Resazurin is an indicator colorimetric that changes in response to a cel-
lular metabolic reduction. Resorufin is the reduced form of resazurin and presents a pink 
color with a high fluorescent intensity that is proportional to the number of alive cells 
respiring. AlamarBlue® is then a direct indicator of cell viability and consequently the cy-
totoxicity of the nanoemulsions. After 24 h incubation, the cells were treated with Alamar 
Blue solution (10%, v/v, in culture medium). After 4 h, absorbance was read at 530 and 
590 nm using an absorbance microplate reader (BioTek Instruments, Winooski, Vermont, 
USA) and cell viability was determined as percent absorbance relative to untreated control 
cells (negative control). 
2.9.2. Comet Assay 
ARPE-19 and HMC3 cells were plated at a density of 50,000 cells/well, and grown to 
confluence in 24-well plates for 7 days. Twelve hours before the experiment, the cells were 
treated with different nanoemulsions (at 20%). After the treatment with nanoemulsions, 
the isolation of cells was carried out, followed by the preparation of a single-cell suspen-
sion to embed the cells in agarose gel. After proceeding the lysis, the cells were submitted 
to alkaline treatment followed by horizontal electrophoresis (30 min, 35 volts, 300 mA), as 
described by Doktorovova et al. [27]. After neutralization, the samples were stained with 
Vista Green DNA Dye and visualized in Inverted Fluorescence Microscope/Coupling 
Stage, Zeiss Axiovert 200M (Carl Zeiss, Germany) using the 20× objective. The assay was 
performed using the OxiSelectTM Comet Assay Kit (Cell Biolabs, Inc., San Diego, CA, 
USA). The results were analyzed using the OpenComet software (www.cometbio.org, ac-
cessed on 15 February 2021); the percentage of DNA in the tail and the olive tail moment 
(OTM) were used to determine the extent of DNA damage. 
2.10. Statistical Analysis 
The results are shown as the mean of three measurements ± standard deviation (S.D), 
whenever applicable. Two-way ANOVA followed by Tukey’s post hoc test was used for 
multi-group comparison. Student’s t-test was used for two-group comparisons. Statistical 
significance was set at p < 0.05. GraphPad Prism V9.0 InStat (GraphPad Software Inc., San 
Diego, CA, USA) was used to carry out the analysis. 
3. Results and Discussion 
Nanoemulsions are commonly referred to as an excellent alternative formulation to 
deliver lipophilic drugs to the eye to increase their bioavailability [28]. In this work, we 
formulated cationic nanoemulsions to provide a high encapsulation rate for the glucocor-
ticoid TA, to enhance its stability, ocular penetration and bioavailability. In order to create 
an electrostatic interaction with the negatively charged cells of the ocular surface and then 
increase the residence time of TA in the locale of action, the surface charge of the 
nanoemulsion (defined by the zeta potential) should be positively charged. The interac-
tion between cationic nanoemulsions with the cornea may offer the opportunity to create 
a depot that will control the release of the drug into deeper eye structures. Thus, the local 
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residence time governs the drug passive diffusion [29]. Nine distinct cationic surfactants 
were used for the production of drug-free nanoemulsions. The composition of the devel-
oped formulations is given in Table 1 [30,31]. 
Table 1. Composition of the developed nanoemulsions. 
Ingredient 
Nanoemulsions 
S1 S2 S3 S4 S5 S6 S7 S8 S9 
CMC (mM) 1.00 0.33 0.8 2.00 3.00 11.00 4.00 0.12 0.08 
SO (% m/V) 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 
T80 (% m/V) 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 
P188 (% m/V) 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
Glycerol (% m/V) 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 
Caption: S1-S9, DABCO and quinuclidine surfactants (for chemical structure, please refer to Fernandes et al. (2021) [25]); 
CMC, critical micellar concentration; SO, soybean oil; T80, Tween 80; P188, Poloxamer 188). 
Pre-formulation studies were previously run, as described by Fernandes et al. [25], 
to obtain the optimal ratio of each ingredient (Table 1). In order to optimize the nanoemul-
sions, the concentration of each cationic surfactant was modified to their critical micelle 
concentration (CMC). Then, nine nanoemulsions were produced, each containing a dif-
ferent cationic surfactant. 
The particle size and zeta potential of the produced nanoemulsions were monitored 
over a period of 120 days. The selection of the best formulation was based on the smaller 
size and lowest polydispersity index (PdI). The smaller the droplet size and PdI, the higher 
the nanoemulsion stability. The zeta potential (ZP) refers to the electrokinetic potential in 
colloidal systems and is determined as the electric potential in the interfacial layer of a 
dispersed medium versus the electrical potential of a stationary layer of the fluid attached 
to the dispersed particle. The pH of the medium, the ionic strength, the temperature and 
the concentration of any additives are the most important factors that affect ZP. ZP results 
can be correlated with the short and long shelf life and/or stability of the nanoemulsions. 
Emulsions that have high values, negative or positive, of ZP are electrically stable. Other-
wise, emulsions with low ZP values are more prone to coagulate or flocculate, possibly 
leading to poor physical stability [32]. Typically, higher ZP values mean that repulsive 
forces surpass attractive forces, which result in stable formulations. 
Table 2 depicts the size and zeta potential variation over time for the nine developed 
formulations. The mean droplet size of all developed nanoemulsions was within the range 
required for ocular administration, which should be between 150 and 300 nm [29]. After 
120 days, stored at 4ºC, the PdI of all developed nanoemulsions was around 0.2 (data not 
shown), which ensures monodispersed formulations [33]. There were no significant dif-
ferences between the mean particle size during the 120 days for all the formulations, S1-
S9 (Table 2). 
A zeta potential value between +20 and +40 mV is required to create an energy barrier 
between the droplets and to avoid coalescence, and these values are required in formula-
tions to be used in ocular delivery [34]. The changes encountered in ZP in all developed 
nanoemulsions were attributed to the dynamic properties of cationic surfactants which 
detach/reattach from the surface of the droplets over time. 
The mean size and zeta potential variations were also recorded for the nanoemul-
sions loading TA (TA-NE) (Table 3). 
Table 2. Mean size and zeta potential variations of the developed nine nanoemulsions without TA, stored at 4 °C, over a 
period of 120 days. Results are the mean of three replicates ± standard deviation (S.D.). Statistical significance * p < 0.05; ** 
p < 0.01; *** p < 0.001; **** p < 0.0001 vs. day 0. 
Mean Particle Size (nm) 
Day S1 S2 S3 S4 S5 S6 S7 S8 S9 
0 220.7 ± 2.9 242.3 ± 8.5 257.3 ± 8.4 245.3 ± 7.7 226.9 ± 4.4 243.3 ± 4.7 233.0 ± 4.7 251.6 ± 9.6 241.2 ± 3.6 
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1 231.4 ± 4.8 241.4 ± 3.9 263.7 ± 7.9 242.4 ± 8.8 231.1 ± 3.9 240.4 ± 8.0 230.4 ± 7.9 257.8 ± 7.9 252.3 ± 3.4 
3 224.6 ± 4.3 240.8 ± 5.9 265.6 ± 9.7 242.9 ± 5.6 235.3 ± 9.0 239.3 ± 6.9 236.9 ± 8.7 254.5 ± 6.6 251.1 ± 5.8 
7 234.7 ± 9.1 241.5 ± 5.5 263.6 ± 7.4 245.9 ± 7.6 233.4 ± 6.7 242.0 ± 6.9 234.7 ± 12.1 258.0 ± 0.9 253.2 ± 6.4 
14 231.9 ± 9.0 242.2 ± 6.6 255.2 ± 9.8 244.7 ± 11.2 233.5 ± 7.2 240.8 ± 8.5 229.8 ± 9.2 256.9 ± 8.1 250.9 ± 6.8 
28 227.4 ± 10.5 241.1 ± 4.0 265.6 ± 8.5 246.5 ± 9.4 231.2 ± 6.0 239.0 ± 3.5 230.8 ± 5.4 255.3 ± 7.9 253.2 ± 3.8 
60 231.6 ± 9.6 240.1 ± 7.9 264.6 ± 6.2 246.0 ± 5.7 230.9 ± 8.6 230.2 ± 5.6 235.2 ± 5.9 254.3 ± 5.2 245.3 ± 1.3 
120 215.4 ± 1.0 232.2 ± 3.5 257.0 ± 7.2 235.1 ± 8.3 226.7 ± 3.5 233.3 ± 7.1 223.7 ± 7.9 236.3 ± 5.4 243.6 ± 6.1 
ZP (mV) 
Day S1 S2 S3 S4 S5 S6 S7 S8 S9 
0 71.6 ± 0.4 51.1 ± 3.1 41.0 ± 1.5 49.5 ± 0.7 63.8 ± 1.5 41.0 ± 1.5 68.4 ± 1.5 39.9 ± 1.2 44.3 ± 0.5 
1 
53.8 ± 0.1 
**** 
44.3 ± 2.0 
**** 
35.6 ± 0.7 
** 
46.3 ± 1.3 60.8 ± 2.1 43.7 ± 1.2 68.4 ± 2.1 
35.5 ± 1.3 
* 
42.2 ± 1.2 
3 
64.2 ± 2.7 
**** 
43.4 ± 1.7 
**** 
31.4 ± 1.7 
**** 
48.1 ± 0.7 59.6 ± 2.1 45.2 ± 1.8 64.9 ± 0.9 
23.7 ± 0.9 
**** 
34.1 ± 1.0 
**** 
7 
53.4 ± 2.6 
**** 
37.8 ± 0.4 
**** 
29.9 ± 0.8 
**** 
47.7 ± 1.3 
57.9 ± 2.6 
** 
38.6 ± 1.9 
62.2 ± 0.7 
*** 
28.9 ± 2.1 
**** 
30.5 ± 0.2 
**** 
14 
62.8 ± 1.3 
**** 
45.6 ± 1.6 
** 
37.1 ± 1.9 47.5 ± 0.8 
58.7 ± 2.0 
** 
38.9 ± 0.4 69.6 ± 1.3 
29.7 ± 2.4 
**** 
26.2 ± 0.9 
**** 
28 
60.1 ± 1.0 
**** 
38.9 ± 0.9 
**** 
29.4 ± 0.6 
**** 
44.7 ± 1.6 
* 
59.4 ± 2.2 
* 
36.9 ± 1.3 66.5 ± 0.7 
31.1 ± 0.7 
**** 
24.3 ± 0.8 
**** 
60 
56.1 ± 0.9 
**** 
34.2 ± 1.1 
**** 
27.4 ± 1.6 
**** 
39.1 ± 2.3 
**** 
53.9 ± 1.9 
**** 
40.8 ± 0.3 
59.3 ± 1.8 
**** 
33.8 ± 0.6 
*** 
29.5 ± 1.3 
**** 
120 69.3 ± 3.3 52.7 ± 0.9 43.1 ± 0.8 58.0 ± 2.1 
**** 
58.6 ± 3.6 
** 
35.7 ± 0.3 
** 
67.0 ± 0.7 36.7 ± 0.45 22.9 ± 0.9 
**** 
Osmolality was recorded for the TA-free and TA-loaded nanoemulsions (Table 4). A 
sample of each nanoemulsion was positioned in a solute-free paper disc in the sample 
holder of the equipment. The cycle measurement initiates when the sample holder is 
pushed into the equipment and takes 80 s. As described in the literature, the formulations 
for ophthalmic use should respect the limits of 171−1711 mOsm/kg to the osmolality [35]. 
However, some authors considered that values of osmolality lower than 100 or higher 
than 640 mOsm/kg could be considered irritants to the eye [36]. The osmolality of tears is 
between 280 and 293 mOsm/kg [37]. All the nanoemulsions with TA have osmolality val-
ues well tolerated by the eye, as opposed to some of the nanoemulsions without the drug 
in their composition. 
Table 3. Mean size and zeta potential variations of the developed nine nanoemulsions with TA, stored at 4 °C over a 
period of 120 days. Results are the mean of three replicates ± standard deviation (S.D.). Statistical significance * p < 0.05; ** 
p < 0.01; *** p < 0.001; **** p < 0.0001 vs. day 0. 
Mean Particle Size (nm) 
Day F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 224.1 ± 1.3 234.7 ± 7.9 257.9 ± 7.2 205.0 ± 5.6 223.0 ± 6.9 247.6 ± 6.8 227.7 ± 5.6 232.6 ± 3.5 218.3 ± 2.5 
1 233.5 ± 7.3 230.8 ± 4.7 251.9 ± 9.5 204.1 ± 4.3 223.1 ± 7.9 253.0 ± 11.1 224.8 ± 6.5 242.3 ± 4.3 217.4 ± 4.7 
3 230.9 ± 7.4 233.6 ± 9.5 259.0 ± 8.3 207.9 ± 5.2 223.2 ± 7.5 254.7 ± 10.0 223.1 ± 6.5 246.8 ± 5.9 215.5 ± 6.8 
7 233.7 ± 2.6 231.5 ± 6.9 260.5 ± 7.0 209.9 ± 6.2 221.2 ± 5.8 250.8 ± 5.6 227.6 ± 5.6 245.3 ± 5.4 218.7 ± 5.5 
14 229.4 ± 7.5 233.1 ± 5.5 254.7 ± 4.6 205.4 ± 3.6 221.0 ± 6.6 249.4 ± 6.3 225.5 ± 5.2 229.7 ± 4.3 216.9 ± 2.7 
28 
241.0 ± 11.2 
* 
230.0 ± 6.0 254.1 ± 6.6 206.5 ± 6.4 219.9 ± 5.0 248.3 ± 3.9 216.1 ± 5.2 242.9 ± 5.7 219.4 ± 5.6 
60 226.9 ± 3.2 234.3 ± 6.6 258.5 ± 9.1 209.7 ± 3.7 220.4 ± 6.0 243.3 ± 7.7 221.6 ± 6.8 243.3 ± 6.6 220.0 ± 5.8 
120 227.4 ± 6.7 223.3 ± 4.9 243.6 ± 3.8 202.8 ± 3.3 210.1 ± 6.3 243.3 ± 1.2 214.7 ± 5.3 230.5 ± 1.7 213.0 ± 5.3 
ZP (mV) 
Day F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 68.2 ± 1.9 41.2 ± 0.4 44.6 ± 1.2 65.1 ± 1.2 65.1 ± 2.7 48.3 ± 1.1 55.9 ± 1.4 44.9 ± 0.5 41.5 ± 0.2 
1 
46.6 ± 1.1 
**** 
50.3 ± 1.9 
**** 
56.8 ± 0.4 
**** 
66.4 ± 1.7 62.4 ± 2.3 
44.2 ± 0.6 
* 
56.8 ± 1.5 41.3 ± 2.9 42.5 ± 0.5 
3 
58.6 ± 1.7 
**** 
43.0 ± 1.0 45.2 ± 1.0 
59.5 ± 1.7 
*** 
60.2 ± 2.3 
** 
43.9 ± 0.8 
* 
61.9 ± 1.0 
*** 
32.0 ± 1.0 
**** 
40.8 ± 0.9 
7 
51.4 ± 1.8 
**** 
36.8 ± 1.3 
* 
39.7 ± 0.1 
** 
59.1 ± 2.1 
*** 
57.8 ± 4.2 
**** 
43.7 ± 0.5 
** 
55.6 ± 1.1 
31.6 ± 0.9 
**** 
41.0 ± 1.7 




60.2 ± 2.9 
**** 
37.5 ± 1.4 43.9 ± 2.0 61.9 ± 0.9 
57.8 ± 2.1 
**** 
40.6 ± 1.2 
**** 
53.0 ± 1.4 46.1 ± 0.5 40.0 ± 0.9 
28 
36.5 ± 1.1 
**** 
36.6 ± 0.6 
** 
51.2 ± 1.7 
**** 
60.5 ± 1.2 
** 
57.6 ± 1.7 
**** 
41.9 ± 1.3 
**** 
71.2 ± 2.2 
**** 
37.0 ± 1.5 
**** 
35.8 ± 0.5 
*** 
60 
52.6 ± 1.8 
**** 
36.4 ± 1.3 
** 
48.8 ± 1.0 
* 
49.5 ± 1.6 
**** 
56.5 ± 2.2 
**** 
43.5 ± 1.0 
** 
54.5 ± 0.4 
32.6 ± 0.7 
**** 
32.5 ± 0.4 
**** 
120 
61.1 ± 2.0 
**** 
48.6 ± 1.7 
**** 
58.5 ± 1.1 
**** 
63.9 ± 1.8 66.5 ± 1.3 
38.9 ± 1.8 
**** 
64.2 ± 1.1 
**** 
35.7 ± 0.4 
**** 
31.7 ± 0.8 
**** 
Table 4. Osmolality of nanoemulsions with and without TA. 
Nanoemulsion without TA mOsm/kg Nanoemulsion with TA mOsm/kg 
S1 140 F1 186 
S2 160 F2 176 
S3 147 F3 186 
S4 164 F4 172 
S5 172 F5 180 
S6 190 F6 188 
S7 183 F7 170 
S8 160 F8 184 
S9 153 F9 189 
The minimum inhibitory concentration (MIC) refers to the lowest concentration of an 
antimicrobial drug and/or formulation that is able to inhibit the growth of a microorgan-
ism after incubation. The species of Candida are the most common cause of invasive infec-
tions provoked by yeast. These species are the predominant causative pathogens of noso-
comial bloodstream infections. In the case of ocular infections, the presence of Candida in 
ocular tissues causes a series of complications that potentially promote defects in the vis-
ual field. The antifungal treatment should thus start immediately [38]. Candida albicans is 
the most predominant species that causes infection in the eye, namely endogenous yeast 
endophthalmitis, for example [39], and about 10–25% of infections provoked by Candida 
result in ocular candidiasis [40]. The MIC values of the nanoemulsions against Candida 
albicans are shown in Table 5. 
Table 5. Minimum inhibitory concentration (MIC) of triamcinolone acetonide-loaded nanoemul-
sions determined against Candida albicans. 
TA-Nanoemulsions Fungistatic Activity (MIC), µg/mL 
F1 2.4 ± 0.1 
F2 11.9 ± 1.3 
F3 6.5 ± 0.5 
F4 2.1 ± 0.1 
F5 29.7 ± 1.7 
F6 4.8 ± 0.7 
F7 6.3 ± 0.1 
F8 8.1 ± 0.2 
F9 9.8 ± 1.1 
The lowest MIC (2.4 μg/mL) was recorded for F1, whereas the highest MIC (29.7 
μg/mL) belonged to F5. Nevertheless, all the formulations had a low minimum inhibitory 
concentration, which indicates that all the nanoemulsions have a potential fungistatic ef-
fect. 
Considering that all TA-loaded nanoemulsions have antifungal properties, they were 
subject to rheological analyses. A frequency sweep test is a useful tool as it allows the 
determination of the viscoelastic properties of a sample as a function of timescale. The 
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parameters obtained are described as storage elastic modulus (G’), the viscous loss mod-
ulus (G”) and the complex viscosity (η* or ETA). The G’ is normally used as a measure of 
the elastic component of the sample, and the loss modulus is used as a measure of the 
viscous component [41]. The frequency sweep test was conducted at a frequency range of 
0.1 to 10Hz and a constant stress amplitude of 5 Pa. The frequency range was the limit of 
the linear viscoelastic region determined before the beginning of the assay. The linear vis-
coelastic region is the range in which the assay can be carried out without destroying the 
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Figure 1. Rheological profiles of the storage modulus (G’), loss modulus (G’’) and the complex viscosity (η*) of triamcino-
lone acetonide-loaded nanoemulsions at a constant stress amplitude of 5 Pa. 
The behavior is similar in all the developed nanoemulsions containing the glucocor-
ticoid. The profiles show that the elastic modulus (G’) is dominant over the viscous mod-
ulus (G’’) in all the samples and is dependent on the frequency applied. The storage and 
loss modulus illustrated an increasing trend as a consequence of increasing the frequency. 
At low frequencies, all nanoemulsions present a low modulus that increases at high fre-
quencies. The increase in the frequency was followed by an increase in viscosity in all the 
samples studied. It is described that at higher frequencies, the time to enable polymer 
chains to untangle is limited and their mobility is compromised, whereas at low frequen-
cies they have the time necessary to untangle and are more mobile. Therefore, the higher 
frequencies are responsible for the increase in elasticity once the polymer chains have less 
mobility, and consequently are incapable of untangling to initiate the deformation of the 
sample [42]. The rheological results show that at the maximum frequency studied, i.e., 10 
Hz, the value of G’’ is smaller than G’, and, as described previously, both are dependent 
on the frequency, which indicates short relaxation times [43]. These relaxation times are a 
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The next step was the determination of the encapsulation parameters for all nine for-
mulations with viscoelastic properties. The results are summarized in Table 6. 
Table 6. Encapsulation efficiency and loading capacity of the TA into nanoemulsions. 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 
% EE 95.438 ± 0.070 83.650 ± 6.874 91.494 ± 0.989 91.083 ± 4.501 93.000 ± 0.675 86.416 ± 1.422 93.850 ± 1.233 90.455 ± 0.345 90.327 ± 0.652 
% LC 0.238 ± 0.001 0.196 ± 0.017 0.227 ± 0.002 0.219 ± 0.011 0.230 ± 0.001 0.218 ± 0.003 0.231 ± 0.003 0.226 ± 0.001 0.224 ± 0.001 
The initial concentration of TA was 50 μg/mL. The lowest %EE and %LC were ob-
tained for F2, whereas the highest values were recorded for F9. The high encapsulation 
parameters recorded for all nanoemulsions were attributed to the lipophilic character of 
the drug, which was kept within the inner oil phase of nanoemulsions during their pro-
duction. 
Aiming at the evaluation of the potential cytotoxic effect of TA-NE, the ARPE-19 and 
HMC3 cell lines were exposed to the samples for 24 h. The effect of the nanoemulsions on 
the viability of the cells was measured by AlamarBlue® assay. In vitro cytotoxicity results 
are depicted in Figures 2 and 3 for ARPE-19 and HMC3 cell lines, respectively. 
The hydrogen peroxide (H2O2) was used as a positive control (at 1 mM, in culture 
medium, for 24h) and culture media, DMEM/F12, as a negative control. The other control 
was performed by adding water to culture medium, at the same percentage as that present 
in the nanoemulsions, i.e., 5%, 10% and 20%. After the administration in the eye, the 
nanoemulsion suffers a physiological dilution process. The dilution that occurs is 1:5 (v/v) 
[44], i.e., at 20%. Thus, the study was performed with nanoemulsions at 20% and two ad-
ditional dilutions, 10% and 5%. The results show that the nanoemulsions produced with 
the surfactants 8 and 9, i.e., F8 and F9, respectively, were non-toxic for the ARPE-19 cell 
line at all tested concentrations (Figure 2). These results are in line with the concentration 
of TA used in all the dilutions, as the viability of the cells exposed to free TA was not 
compromised (Figure 2). Thus, the amount of TA used in the production of the nanoemul-
sions was considered to be safe with no toxic effect on ARPE-19 cells. 




Figure 2. ARPE-19 cell viability upon exposure to TA-loaded nanoemulsons (F1-F9) recorded after 24 h of incubation. 
Culture media DMEM/F12 and 1 mM H2O2 were used, respectively, as negative and positive controls. The other control 
was performed by adding water to the culture medium, at the same percentage as that present in the nanoemulsions 
(%H2O), i.e., 5% (A), 10% (B) and 20% (C). The results are the mean of three replicates, and the bars represent the the mean 
± standard deviation (S.D.). Statistical significance; **** p < 0.0001 vs. negative control (DMEM/F12). H2O2: hydrogen per-
oxide; TA-NE: nanoemulsions loading TA. 
After obtaining the cytotoxicity results for the ARPE-19 cells, the cytotoxic effect of 
F8 and F9 was studied in the HMC3 cell line (Figure 3). As the drug needs to reach micro-
glial cells, the tested nanoemulsion concentrations in HMC3 cells were 10%, 5% and 2.5%. 
It is expected that the drugs administrated to the eye suffer dilutions with the lachrymal 
fluids. Again, the cells were seeded in a 24-well plate for 7 days, with replacement of the 
medium every two days. After 7 days, the medium was changed, and the cells were ex-
posed to nanoemulsions 8 and 9 (F8 and F9) for 24 h. After this period of incubation, the 
resazurin (10%) was added to each well, for 4 h, and then the plate was read at 530 and 
590 nm using a fluorescence microplate reader. 




Figure 3. HMC3 cells viability after exposure to F8 and F9 for 24 h, at three different concentra-
tions (10%, 5% and 2.5%). Cell culture medium (DMEM/F12) and culture medium supplementa-
tion with 1 mM H2O2 were used, respectively, as negative and positive controls. The results are the 
mean of three replicates, and the bars represent the mean ± standard deviation (SD). Statistical 
significance * p < 0.05; **** p < 0.0001. Abbreviation: H2O2, hydrogen peroxide. 
Figure 3 shows that the higher the dilution, the higher the cytotoxicity of nanoemul-
sions, i.e., there is an increase in the cell viability with the decrease in concentration. With 
respect to the results obtained for 10% F8 and 10% F9, i.e., the more concentrated ones, 
compared to the results obtained in the cytotoxicity assay for the ARPE-19 cell line, the 
viability of the HMC3 cells is much more compromised in the case of F8, and there was a 
decreased viability in the cells exposed to F9. For the other concentrations (5% and 2.5%), 
there was an improvement in the viability of the cells compared to the most concentrated 
nanoemulsion. However, in the case of 5%, the viability of the HMC3 cell was lower than 
that obtained for APRE-19 cells in the same conditions. These nanoemulsions are thus 
more harmful to the microglial cells (HMC3) than to the retinal pigment epithelium cells 
(ARPE-19). 
The surface of the eyes is covered with tear film. The tear film is a thin fluid layer that 
is the interface of the eye surface with the environment, and is approximately 3 μm thick 
and 3 μL in volume [45]. The tear film is constituted of three layers, a lipid layer, water 
layer and mucin layer. These constituents keep the eye healthy and without infections. In 
terms of surface tension, the tear film is normally destabilized when the value of the sur-
face tension of the eyedrops used is lower than the value of the tear film. The surface 
tension could be described as the ability of a surface of a portion of liquid to be attracted 
by another surface or portion of liquid. Higher surface tension makes stronger interactions 
between the molecules of the liquids. The temperature decreases the surface tension due 
to the interactions inside the liquid being lower when compared to the heat-moving forces 
which promote the stability of the formulations [25]. 
The surface tension of the lachrymal fluid is around 40 to 50 mN/m[44]. Surface ten-
sion measurements were carried out at 36.7 °C with n = 14 for both nanoemulsions. The 
surface tension of the prepared TA nanoemulsions are 41.05 ± 2.06 mN/m for F8 and 43.37 
± 1.46 mN/M for F9. Lallemand et al. [29] reported that all the cationic nanoemulsions for 
ocular delivery should have surface tension similar to the tears, which confirms the po-
tential of the produced nanoemulsions. 
The comet assay reveals the genotoxic effects of nanoemulsions with TA on the 
ARPE-19 and HMC3 cell lines. The alkaline comet assay is a sensitive assay to detect DNA 
damage and has the ability to sensitively measure the strand breaks and other lesions that 
are converted into strand breaks under alkaline conditions. The comet assay does not di-
rectly measure the number of specific DNA lesions but rather measures the migration of 
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DNA in the agarose gels as a result of the relaxation induced by strand breaks under al-
kaline conditions. The results shown in Figure 4, obtained with cells exposed to 
nanoemulsions at 20%, illustrate the comet tails indicative of DNA damage. In order to 
quantify the extent of induced DNA breaks in the cell lines, the intensity of the comet tails 
was scored (Figure 5). 









Figure 4. Genotoxic effects induced by nanoemulsions with TA in ARPE-19 and HMC3 cell lines. 
Images obtained with 20× objective. 
 
Figure 5. Genotoxic effects induced by F8 and F9 nanoemulsions in ARPE-19 and HMC3 cell lines. 
The bars indicate the % of DNA in the comet tail (mean ± SD). Mean was calculated by the Open-
Comet software. Statistical significance: * p < 0.05; **** p < 0.0001. 
As shown in Figure 5, in both cell lines, nanoemulsions at 20% increase the % of DNA 
in the comet tail as compared to the respective control. The scoring of comet tails in terms 
of % DNA in the tail showed a significant increase in DNA damage, after exposure to 20% 
F8, of HMC3 cells. In the case of F9, there was no significant DNA damage when com-
pared to the control in both cell lines; thus, F9 does not lead to genotoxic effects. If we 
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related the cytotoxicity and genotoxic assays, the nanoemulsion F8 presented higher tox-
icity in both cell lines (Figures 2 and 3); hence, the increase in genotoxicity in the comet 
assay with F8 corroborates the previous results. The distance between the center of the 
head and the center of the tail, i.e., the olive tail moment, is represented in Table 7. The 
olive tail moment is defined as the product of the tail length and the fraction of total DNA 
present in the tail. The tail moment includes an amount of the lowest detectable size of 
migrating DNA and the quantity of broken pieces of DNA. The quantity of migrating 
DNA is revealed by the comet tail length and the amount of broken pieces of DNA is 
exposed by the intensity of DNA in the tail of the comet [46]. The increase in the olive tail 
moment represents higher DNA damage. In both cell lines, i.e., ARPE-19 and HMC3, F8 
caused increased DNA damage. 
Table 7. Olive tail moments for formulations F8 and F9 in both cell lines, ARPE-19 and HMC3. 
Olive tail moment values describe the variations in DNA distribution within the comet tail. Values 
are presented as the mean ± standard deviation (S.D). 
Olive Tail Moment (OTM) 
Formulation ARPE-19 HMC3 
Control 4.77 ± 8.16 3.94 ± 7.45 
F8 22.69 ± 27.34 145.45 ± 41.96 
F9 17.23 ± 34.83 37.80 ± 41.99 
4. Conclusions 
The residence time of a cationic nanoemulsion is prolonged on the ocular surface, 
attributed to the electrostatic attraction between the cationic lipid nanodroplets and the 
negatively charged ocular surface. These typical properties of the produced nanoemul-
sions are beneficial for the administration of drugs on the ocular surface. In this work, we 
successfully developed a suitable nanoemulsion for the ocular delivery of triamcinolone 
acetonide. Both nanoemulsions, F8 and F9, were found to be stable for 2 months when 
stored at 4 °C, and have osmolality values compatible with ocular administration. The 
surface tension was 41.05 ± 2.06 mN/m for F8 and 43.37 ± 1.46 mN/M for F9, which are 
similar to the values of the lachrymal fluid. The in vitro results of the cytotoxic assay show 
high values of viability for ARPE-19 and HMC3 cells, after administration of F8 and F9 in 
different concentrations, which translates the safety of the nanoemulsions produced. 
However, in the comet assay (genotoxic test), the F8 revealed higher DNA damage in both 
cell lines (ARPE-19 and HMC3) when compared to the results obtained for F9 in the same 
concentration. Cationic nanoemulsions have been described as one of the most suitable 
formulations for ocular drug delivery to target both the anterior and posterior segments 
of the eye, attributed to their interaction with the corneal membranes, increasing the re-
tention time of drugs in the eye. Aiming to avoid the risk of toxicity commonly reported 
with the use of cationic surfactants in drug formulations, in this work we developed 
nanoemulsions based on the use of the surfactant at its critical micelle concentration 
(CMC), i.e., the concentration at which micelles are spontaneously formed. A higher CMC 
of the cationic surfactant (S8) was used for F8 when compared to F9, which may be re-
sponsible for the increased genotoxicity reported for F8. From our studies, we select F9 as 
the most suitable cationic nanoemulsion for ophthalmic administration due to its nontoxic 
profile in the resazurin assay and its lower genotoxicity in the comet assay. 
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